Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label elexacaftor + tezacaftor + ivacaftor in cystic fibrosis with F508del and gating or residual function mutation
2019-000833-37Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Long-term safety and tolerability. Started Jun 2019; status: completed.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2019-000833-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000833-37.